Pfizer Will Shift Focus to Dividends and Share Buybacks, Execs Say
- Order Reprints
- Print Article
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
https://www.barrons.com/articles/pfizer-stock-dividends-buybacks-earnings-1ddb89b
The big pharma company Pfizer has been on an M&A hot streak over the past couple of years, digging into its Covid-19 vaccine and therapeutic windfalls to go on a big-ticket buying spree.
An error has occurred, please try again later.
Thank you
This article has been sent to
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.